Berry Genomics disclosed its earnings forecast, projecting a net loss attributable to shareholders of 38 million to 56 million yuan for the first half of 2026, compared with a loss of 27.2425 million yuan in the same period last year. The net loss after deducting non-recurring items is expected to be 37 million to 55 million yuan, versus a loss of 28.5895 million yuan a year earlier. The company attributed the performance change mainly to industry cyclical fluctuations and intensified market competition, along with an increase in bad debt provisions for accounts receivable and slight rises in selling, administrative, and research and development expenses. The company continues to increase R&D investment, advancing multiple research projects, which has driven up overall R&D expenses. Non-recurring gains and losses are estimated at about 1 million yuan, primarily from gains on disposal of fixed assets and government subsidies.
Berry Genomics Co LtdCompany projects a larger net loss for first-half 2026 compared to prior year.